One of the challenges that transcatheter aortic valve replacement (TAVR) continues to face is percutaneous access closure with percutaneous closure systems (PCS). However, several systems have been developed, either by plug—such as the MANTA system—or by suture (SU)—such as the ProStar and ProGlide systems. Both of these have been tested in different analyses, but to<a href="https://solaci.org/en/2023/04/12/percutaneous-access-closure-in-tavr-are-devices-similar/" title="Read more" >...</a>
The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with large effective orifice and low transvalvular gradient associated to an acceptable complications rate. With this study, the Hydra will obtain the CE mark and go after FDA approval (just as all new devices). This study looked at safety<a href="https://solaci.org/en/2022/01/19/hydra-ce-new-models-for-tavr-development/" title="Read more" >...</a>
This meta-analysis which included the 4 large randomized studies on transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) in low-risk patients recently published in JACC, showed TAVR is associated with significant lower mortality compared against SAVR at one year follow up. These results add to the mounting evidence showing that when it<a href="https://solaci.org/en/2019/10/28/meta-analysis-of-large-tavr-studies-on-low-risk-evidence-is-consistent/" title="Read more" >...</a>
Courtesy of Dr. José Álvarez. The RESPECT trial is a multicenter randomized trial with blinded adjudication of end-point events. It randomly assigned patients from 18 to 60 years of age who had a patent foramen ovale (PFO) and a history of cryptogenic ischemic stroke to undergo closure of the PFO with the Amplatzer device plus medical<a href="https://solaci.org/en/2017/09/15/long-term-results-of-the-respect-study-favor-closure-with-the-amplatzer-device/" title="Read more" >...</a>
At present, there is increasing interest in the microvascular function of patients with and without obstructive coronary artery disease of different ages. However, these “physiological” effects of age on microvascular function have never been directly quantified on patients without obstructive CAD. Prior studies have focused on patients with angina and obstructive CAD, and the effects<a href="https://solaci.org/en/2024/06/28/age-and-microvascular-function-in-patients-without-obstructive-coronary-artery-disease/" title="Read more" >...</a>
Cath lab activation—and everything that entails—within 20 minutes was associated with the target of performing primary angioplasty in under 2 hours in at least 75% of patients. Historically, door-to-balloon time was measured, which provided a rough idea of where there could be flaws to fix. This is particularly true in the case of patients who need to<a href="https://solaci.org/en/2020/08/15/early-activation-to-speed-up-treatment-of-infarcted-patients/" title="Read more" >...</a>
The pandemic tsunami of COVID-19 has hit all cath lab services, especially those performing primary PCI. Passively waiting for the first patient suspected of infection only to improvise in the early hours means heading for disaster. Several scientific societies have published recommendations, but not based on clear data. It seems pertinent to bear in mind<a href="https://solaci.org/en/2020/06/12/priorities-in-the-cath-lab-to-escape-covid-19-tsunami/" title="Read more" >...</a>
This prospective study analyzed patients with critical lower limb ischemia (due to complex, multiple lesions in several places) who were treated uniformly with common femoral artery endarterectomy combined with angioplasty to improve inflow and/or outflow. This hybrid treatment, which must be carried out by a team, can be greatly beneficial for this high-risk patient group<a href="https://solaci.org/en/2020/05/26/common-femoral-artery-endarterectomy-plus-angioplasty-in-critical-ischemia/" title="Read more" >...</a>
This study sought to randomly compare the double-layer Roadsaver stent (Terumo) with the single-layer Carotid Wallstent device (Boston) in association with either distal filter-like embolic protection device FilterWire (Boston) or proximal protection device Mo.Ma (Medtronic) in patients with lipid-rich carotid plaques. This is a very interesting work because there are no head-to-head simultaneous comparisons between<a href="https://solaci.org/en/2020/05/04/the-whole-toolkit-tested-in-carotid-artery-stenting/" title="Read more" >...</a>
A large proportion of patients undergo primary angioplasty beyond the timelines recommended by clinical practice guidelines. These patients have poorer 5-year outcomes compared with those subjected to a pharmaco-invasive strategy. ST-segment elevation myocardial infarction guidelines recommend primary angioplasty as the strategy of choice within 120 min after a diagnostic electrocardiography. If that is not possible, thrombolytic<a href="https://solaci.org/en/2020/03/18/5-years-of-fast-mi-if-unable-to-meet-the-timeline-thrombolization-is-the-way-to-go/" title="Read more" >...</a>